NanoLogix Provides 6-hour MRSA Results at UTHSC - Houston. Welcomes New Science Advisory Board Members
07 March 2011 - 9:30PM
Business Wire
NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the
rapid detection and identification of live-cell microorganisms,
announces preliminary results of MRSA (Methicillin-resistant
Staphylococcus aureus) testing at the University of Texas Health
Science Center - Houston. Dr. Jonathan Faro, M.D., Ph.D. has found
NanoLogix technology is able to deliver results for MRSA in 6
hours, as opposed to conventional culture-based testing wait times
of 24 to 48 hours. Dr. Faro is lead researcher in an ongoing Group
B Streptococcus (GBS) clinical trial using NanoLogix test kits at
UTHSC. Scientific papers detailing the first two phases of the GBS
clinical trial are currently being submitted for publication in
peer-reviewed journals.
An interview with Dr. Faro explaining his rapid live-cell
results can be found at www.nanologix.com.
NanoLogix Announces New Science Advisory Board
Members
NanoLogix is pleased to welcome four exceptionally talented
individuals to its Science Advisory Board. New members include Dr.
Megan Barnhizer, D.V.M.; Dr. Sebastian Faro, M.D., Ph.D.; and Dr.
Allan Katz, M.D. and Dr. Gwen R. Acker Wood, Ph.D., J.D. They join
existing Science Board members Ahmer Kodvawalla, M.S., M.B.A.;
Hilda Diaz, M.S.; and Dr. Clifford Watts, M.D.
"We are very pleased to welcome these new members to the Science
Advisory Board,” said Bret Barnhizer, NanoLogix CEO. “The new
members add depth and valuable expertise to our SAB as the UTHSC -
Houston approaches the conclusion of our GBS clinical trial and we
begin the application process for FDA approval.”
Dr. Allan Katz, M.D., professor and Vice-Chairman of Obstetrics
and Gynecology at the University of Texas Medical School in
Houston, and chief of Gynecology at Hermann Memorial Hospital in
Houston stated, “We have relied far too long on traditional culture
based technology, and this practice has undoubtedly contributed
towards the development of microbial resistance. The technology
offered by NanoLogix is exciting as it promises more rapid results
in a time when it most matters to the patient. It also holds vast
potential as the technology extends beyond GBS and MRSA and tests
can be performed by almost anyone, in any corner of the world.”
Dr. Sebastian Faro, M.D., Chief of Obstetrics and Gynecology at
LBJ Hospital in Houston, Texas, said, “This is an extremely
exciting time to be working on the development of diagnostic tests
to identify pathogenic bacteria in a rapid manner. This technology
from NanoLogix will revolutionize the process of identifying
disease causing bacteria and facilitate a more direct approach in
choosing appropriate antibiotic therapy.”
NanoLogix New Science Advisory Board Members
Megan Barnhizer, D.V.M.
Dr. Megan Barnhizer has been a veterinarian in clinical practice
since graduating from the Ohio State University College of
Veterinary Medicine in 1999. Her addition to the Science Advisory
Board comes at a time of marked increase in interest in NanoLogix
detection and diagnostic technologies from international and
domestic corporations, agencies and organizations with a focus on
livestock and animal husbandry.
Sebastian Faro, M.D., Ph.D.
Dr. Sebastian Faro brings an extensive body of knowledge
concerning obstetrics, gynecology, and infectious diseases to the
NanoLogix Science Advisory Board. Dr. Faro is Chief of Obstetrics
and Gynecology at LBJ Hospital in Houston, Texas. He is also the
current Vice-Chair of the Obstetrics, Gynecology, and Reproductive
Sciences Department at the University of Texas Health Science
Center in Houston. Dr. Faro has published at least 149 articles in
peer-reviewed medical publications and served as Editor-in-Chief of
the Infectious Diseases in Obstetrics and Gynecology journal for 13
years.
Allan Katz, M.D.
Dr. Allan Katz brings to the advisory board over forty years of
experience in the fields of women’s health and pregnancy, including
the management of high risk pregnancies. Dr. Katz is a Robert K.
Creasy Professor and Vice-Chairman of Obstetrics and Gynecology at
the University of Texas Medical School at Houston. Dr. Katz is also
Chief of Gynecology at Hermann Memorial Hospital.
Gwen R. Acker Wood, Ph.D. J.D.
Gwen R. Acker Wood is a U.S. and foreign patent attorney, who
brings a wealth of medical, biotechnology and life sciences patent
experience to NanoLogix. Dr. Wood handles patent filings for
NanoLogix through her firm, Acker Wood IP Law. Prior to becoming a
patent attorney, Dr. Wood was a research scientist in the areas of
neurochemistry and psychoimmunology. In addition, she served as an
adjunct professor of biology, nutritional science and advanced
pathophysiology at New York University, as well as adjunct
professor of biology and advanced pathophysiology at Duquesne
University.
More information on the Nanologix Science Advisory Board can be
found here or by going to
http://www.nanologix.com/team.html#Science%20Advisory%20Board%20Members.
NanoLogix General Shareholder Meeting Rescheduled
The NanoLogix general shareholder meeting is being rescheduled
and will be held in the middle of September 2011. Additional
details concerning the date and time of the meeting will be
announced as September grows closer. This shareholder meeting will
be held virtually, through the Broadridge Virtual Shareholder
Meeting service. Further information regarding the process can be
found at http://www.broadridge.com/vsm/.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024